Latest News

All Articles

Filter by:
Topic
Advocacy

Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey

May 16, 2023

The survey was developed by the HOPA Practice Outcomes and Professional Benchmarking Committee (POPBC) and distributed between March 2021 and January 2022

Mantle-Cell Lymphoma
Journal Club

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

May 16, 2023

Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (M

colonoscopy image
HOPA News Late Breaking News

Late-Breaking HOPA News: Colorectal Cancer Screening Updates & Review of NordICC

March 24, 2023

The Nordic-European Initiative on Colorectal Cancer (NordICC) trial is the first randomized controlled trial (RCT) to evaluate efficacy of CRC screening on risk of CRC development and related death.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Retifanlimab-dlwr

March 22, 2023

Bernard Marini, PharmD, BCOP, Clinical Pharmacist Specialist at University of Michigan College of Pharmacy writes about Retifanlimab-dlwr.

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Pirtobrutinib

January 27, 2023

Andy Hawn, 2025 PharmD Candidate and Erin Kelley, PharmD, BCOP at the Masonic Cancer Clinic Infusion Pharmacy write about Pirtobrutinib

Drug Updates

Pharmacist’s Application to Practice: Elacestrant

January 27, 2023

Monica Chintapenta, PharmD, BCOP, Pharmacist Clinical Specialist at Parkland Health and Hospital Systems writes about Elacestrant

Tools and Resources Late Breaking News

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

January 18, 2023

BPS Announces Professional Development Programs Approved for the Recertification of Board-Certified Pharmacists beginning in January 2024

Journal Club Journal Club

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

January 02, 2023

Olutasidenib, with or without azacitidine, was well tolerated and showed meaningful clinical activity in patients with IDH1-mutated acute myeloid leukaemia.

Education

Overcoming Challenges to Provide BiTE and CAR T Cell Therapy at a Community Cancer Center

December 31, 2022

Krista L. Voytilla, PharmD, BCOP, and Chase N. Ayres, PharmD, BCOP, review the technical and clinical issues facing community cancer centers and their pharmacy teams delivering these high-tech treatments.

Pharmacists talking
Education

Reaching the Melting Point: My Time Transitioning from a Solid to a Liquid Tumor Pharmacist

December 30, 2022

Reflection on Personal Impact and Growth

Imaging scan of lung cancer
Tools and Resources Drug Updates

Pharmacist Application to Practice: Adagrasib

December 22, 2022

Sam Palmatier, Pharmacy Intern and Jeff Engle, PharmD, MS, Oncology Pharmacy Manager at Fairview Cancer Clinic – Edina write about

Tools and Resources Drug Updates

Pharmacist's Application to Practice: Mosunetuzumab

December 22, 2022

Bernard Marini, PharmD, BCOP Clinical Pharmacist Specialist – Hematology/Oncology Clinical Associate Professor University of Michigan College of Pharmacy writes about Mosunetuzumab.